A Phase 3 interventional study of Aspirin therapy interruption and Usual treatment by aspirin 100 mg/d in the active comparator arm in MPN and Essential Thrombocythemia, sponsored by Assistance Publique - Hôpitaux de Paris. Status unknown at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-26.
Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 3, Interventional, and Treatment
The hypothesis is that efficient prevention of thrombosis with aspirin at diagnosis becomes less useful once patients have achieved a hematologic response (HR) (modified by amendment 1/03/2017) and/or that this benefit is hampered by an increased hemorrhagic risk especially in elderly patients.
Hence, investigator propose a prospective randomized study to assess the benefit / risk ratio of aspirin maintenance in high risk Essential thrombocythemia (ET) patients, in hematological response (modified by amendment 1/03/2017) on Hydroxyurea.
ET is a myeloproliferative neoplasm (MPN) characterized by a high platelet level. Increased occurrence of thrombosis and hemorrhages are the main complications in ET. In this regard, the key factors defining high risk ET include age over 60 years, past history of thrombosis, platelet > 1500 109/L and to a lesser degree cardiovascular risk factors. These criteria currently serve as therapeutic guidelines for the use of cytoreductive therapy, with hydroxyurea (HU) being the treatment of choice in the first line setting.
The use of antiplatelet agent i.e. low-dose aspirin is also generally recommended. However, the benefit of aspirin has never been formally demonstrated in ET. Only indirect evidence come from the ECLAP study that enrolled patients with polycythemia vera (PV). Of note in the ECLAP study, the efficacy of aspirin was assessed only at diagnosis but not correlated thereafter with the hematological response on cytoreductive therapy.
In general non-MPN population studies, primary prophylaxis with aspirin has been associated with a risk reduction of major vascular events, but an increased risk of hemorrhage, especially considering age and prior gastrointestinal history. In a recent retrospective study, the combination of aspirin and cytoreduction was reported to prevent thrombosis but concomitantly increase the bleeding risk when compared to HU alone , especially in patients older than 60 years, thus questioning the benefits of long term use of aspirin therapy. These data raise the question of the actual benefit of aspirin maintenance, once patients have been efficiently treated with cytoreductive therapy.
Hence, investigator propose a prospective randomized study to assess the benefit / risk ratio of aspirin maintenance in high risk ET patients, in hematological response (modified by amendment 1/03/2017) on Hydroxyurea. Patients for which Aspirin interruption will not be possible because of extra-ET indications will be enrolled in the control observational arm.
157 studies on the registry are indexed under Thrombocytosis; 21 are open to participants now.
This study's planned enrollment of 2,250 is above the median of 51 across 117 interventional studies indexed under Thrombocytosis.
Browse Thrombocytosis studies →Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,505 studies on the registry; 1,006 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Contraception considered effective by the investigator: for women of childbearing and for men whose partner is likely to procreate (added by amendment 01/03/2017)
Exclusion Criteria:
History of haemostasis perturbation not related to ET, associated with a significant risk of hemorrhage or thrombosis (modified by amendment 01/03/2017)
-.• Pregnancy or breastfeeding (added by amendment 01/03/2017)
Other: Aspirin therapy interruption · Drug: Hydroxyurea treatment (HU)
Other: Usual treatment by aspirin 100 mg/d in the active comparator arm · Drug: Hydroxyurea treatment (HU)
Observational arm
Other: No interruption of aspirin in the Observational arm · Drug: Hydroxyurea treatment (HU)
Stop the treatment by aspirin 100mg/d in the experimental arm.
HU+ aspirin maintenance
patient with Contre indication to aspirin or required antithrombotic therapy
HU maintenance
Cumulative incidence of death from vascular origin and other thrombotic and hemorrhagic events (combined endpoint)
Definition of vascular events: Thrombotic events: Myocardial infarction, unstable angina, stroke, transient ischemic attack, peripheral arterial thrombosis, splanchnic or limb deep vein thrombosis, pulmonary embolism, and erythromelalgia Hemorrhagic events: Intracranial or retroperitoneal bleed, overt hemorrhage associated with a decrease in hemoglobin ≥20 g/l or overt hemorrhage requiring a blood transfusion of two red blood cell (RBC) units or more, and hemorrhage of grade \>=2 according to the NCI Common Toxicity criteria (CTC) V.4.0 scale. Deaths will be included as a death from thrombosis or hemorrhage if they satisfied criteria for one of the above diagnoses immediately ANTE-MORTEM or if they had a POST-MORTEM examination confirming the diagnosis. Sudden death of presumed vascular origin without a POST-MORTEM examination will be included as a thrombotic death.
Time frame: at 2-years follow-up
Cumulative incidence and characteristics of vascular complications: thrombosis and hemorrhage, (grade, site, recurrence), assessed yearly over a 5-year follow-up period.
Time frame: at 5 years
Rate of hematological response every 6 months
Hematological response as assessed by European Leukemia Net (ELN) criteria, revised ELN International Working Group on Myeloproliferative Neoplasms Research and Treatment (ELN -IWG MRT).
Time frame: at 5 years
Adverse event (AE) frequency and incidence, comparison in the two arms
Time frame: at 5 years
Number of HU-related nonhematologic toxicities
Time frame: at 5 years
Cumulative incidence of thrombosis
Time frame: at 5 years
Cumulative incidence of hemorrhagic complications
Time frame: at 5 years
Estimation of the progression-free survival
Time frame: at 5 years
Estimation of overall survival
Time frame: at 5 years
Short Form 36 (SF36) Health Survey
Evaluation of quality of life by using SF36
Time frame: through study completion, an average of 1 year
Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF)
Evaluation of quality of life by using (MPN-SAF)
Time frame: through study completion, an average of 1 year
Number of mortality cause.
Time frame: at 5 years
Cumulative incidence of progression to polyglobulia
Time frame: at 5 years
Cumulative incidence of progression to myelofibrosis (MF)
Time frame: at 5 years
Cumulative incidence of progression to myelodysplastic syndrome (MDS)
Time frame: at 5 years
Cumulative incidence of progression AML
Time frame: at 5 years
Frequencies of mutations (JAK2V617F, MPLw515 and CALR) and JAK2V617F allele burden, MPLw515 allele burden and CALR mutation allele burden (in blood DNA) in patients presenting thrombosis or not .
Time frame: at 5 years
Frequencies of mutations (JAK2V617F, MPLw515 and CALR) and JAK2V617F allele burden, MPLw515 allele burden and CALR mutation allele burden in patients in persistent hematological response (modified by amendment 1/03/2017).
responses and intolerance define according to ELN criteria
Time frame: at 5 years
Frequencies of mutations (JAK2V617F, MPLw515 and CALR) and JAK2V617F allele burden, MPLw515 allele burden and CALR mutation allele burden in patient who will lose their hematological response (modified by amendment 1/03/2017).
responses and intolerance define according to ELN criteria
Time frame: at 5 years
Frequencies of mutations (JAK2V617F, MPLw515 and CALR) and JAK2V617F allele burden, MPLw515 allele burden and CALR mutation allele burden in patients presenting intolerance to treatment.
responses and intolerance define according to ELN criteria
Time frame: at 5 years
This study is status unknown, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris